Gilotrif® (afatinib) – Expanded indication
January 16, 2018 - Boehringer Ingelheim announced the FDA approval of Gilotrif (afatinib), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Top